12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Reports Second Quarter 2026 Financial Results and Business Updates
Stockholders Approve Amendment to 2022 Stock Option Plan - Fate Therapeutics
Transforming the Lives of Patients Living with Autoimmune Diseases and Cancer Making Cell Therapies Accessible to AllTM
Reports First Quarter 2026 Financial Results and Business Updates
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics Shows Immune Remodeling in Lupus with FT819 Therapy at ACR 2025
Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report